Abstract: A method for a system backup, includes: backing up a system mapping table before a system file is updated, wherein the system mapping table includes at least one first storage address, and each first storage address corresponds to an address where first system file data is currently stored in a memory; retaining, in response to that the system file is updated, the first system file data in the memory; and storing updated second system file data in the memory and determining an updated system mapping table.

Abstract: A mobile charging apparatus can be detachably assembled to a wearable apparatus body, so as to be assembled and fitted to the wearable apparatus body for charging when the wearable apparatus body needs to be charged, and to be separated from the wearable apparatus body when the wearable apparatus body does not need to be charged.

Abstract: Disclosed is a controllable method for preparing phospholipid micelles, including: S1, preparing small phospholipid vesicles; S2, preparing a graphene thin-layer electrode substrate, S3, incubating, and S4, electroforming phospholipid micelles. According to the present application, lamellar graphene is used as the electrode substrate according to the present application, where a phospholipid bilayer film is firstly spread on the surface of the substrate, and phospholipid micelles are controlled in terms of formation as well as formation state by a certain alternating current electric field on the surface of graphene; the developed method of the present application is unique in design, simple in operation, and has the advantages of fast formation, short preparation cycle and good controllability.

Abstract: Disclosed is a controllable method for preparing phospholipid micelles, including: S1, preparing small phospholipid vesicles; S2, preparing a graphene thin-layer electrode substrate, S3, incubating, and S4, electroforming phospholipid micelles. According to the present application, lamellar graphene is used as the electrode substrate according to the present application, where a phospholipid bilayer film is firstly spread on the surface of the substrate, and phospholipid micelles are controlled in terms of formation as well as formation state by a certain alternating current electric field on the surface of graphene; the developed method of the present application is unique in design, simple in operation, and has the advantages of fast formation, short preparation cycle and good controllability.

Abstract: The invention relates to a water-repellent and lipophilic composite needle-punched nonwoven fabric and a preparation method thereof. The method comprises the following steps: blending a PET fiber and a polyolefin-based fiber in a mass ratio of 3:1-1:3, and performing needle punching to obtain a composite needle-punched nonwoven fabric; carrying out hot-drying treatment on the composite needle-punched nonwoven fabric at 110-160° C. for 40-90 min; and carrying out water-repellent finishing on the hot-dried fabric using 50-70 mL/L of an aqueous solution of a modified resin-based fluorine-free waterproofing agent, and drying to obtain the water-repellent and lipophilic composite needle-punched nonwoven fabric, wherein the water-repellent finishing is dip rolling, the air pressure is 1.8 kPa and the liquid carrying rate is 160-230%.

Abstract: The invention relates to a water-repellent and lipophilic composite needle-punched nonwoven fabric and a preparation method thereof. The method comprises the following steps: blending a PET fiber and a polyolefin-based fiber in a mass ratio of 3:1-1:3, and performing needle punching to obtain a composite needle-punched nonwoven fabric; carrying out hot-drying treatment on the composite needle-punched nonwoven fabric at 110-160° C. for 40-90 min; and carrying out water-repellent finishing on the hot-dried fabric using 50-70 mL/L of an aqueous solution of a modified resin-based fluorine-free waterproofing agent, and drying to obtain the water-repellent and lipophilic composite needle-punched nonwoven fabric, wherein the water-repellent finishing is dip rolling, the air pressure is 1.8 kPa and the liquid carrying rate is 160-230%.

Abstract: An enzyme linked immunosorbent assay (ELISA) method and kit for detecting soluble programmed cell death 5 (PDCD5) protein are provided. The method includes the following steps: (1) contacting a sample to be tested with a solid carrier loaded with a first antibody of PDCD5 protein; (2) adding a second antibody of PDCD5 protein, which is capable to binding to a detecting label; (3) adding the detecting label and detecting the bound detecting label. The soluble PDCD5 in a biological sample from a mammal comprising human can be detected by the ELISA method and kit. The method and kit can be used for detecting the level of PDCD5 protein in plasma, serum, urine, cerebrospinal fluid and synovial fluid so that an auxiliary detection method, for diagnosis of autoimmune disease, inflammation (such as hepatitis), and tumor etc., determination of disease course, observation of therapeutic effect and prognosis and medical guidance, is provided.

Abstract: The invention relates to the use of PDCD5 polypeptides or polynucleotides that code the PDCD5 polypeptides in preparation of sensitizers of chemotherapeutic agents for cancers. The invention also relates to the use of PDCD5 polypeptides or polynucleotides that code the PDCD5 polypeptides to protect normal or diseased tissues or organs from damage or further damage, and to pharmaceutical combinations including chemotherapeutic agents and PDCD5 polypeptides or polynucleotides that code the PDCD5 polypeptides in an amount effective for sensitization. Preferably, the pharmaceutical agents are selected from antibiotic and anti-metabolic agents or any combination thereof.

Abstract: Polypeptides having an amino acid sequence of SEQ ID NO: 2, and having amino acid residues 9 to 27 of SEQ ID NO: 2 are disclosed, which are together named C-terminal polypeptides of CKLF1. Also disclosed is a pharmaceutical composition containing a therapeutically effective amount of the CKLF1 C-terminal polypeptide and pharmaceutically acceptable salts, carrier or excipient. Further disclosed are the polynucleotides encoding the C-terminal polypeptides of CKLF1, and vectors and host cells containing the polynucleotides; the in vitro assays for detecting the expression level of the polypeptide or polynucleotide in a test sample; and the monoclonal or polyclonal antibodies against the polypeptides or active fragments thereof. The polypeptides of the present invention can be pharmaceutically used for treating the HIV infection, allergic disease, allograft rejection, diseases in brain and autoimmune diseases.

Abstract: Polypeptides having an amino acid sequence of SEQ ID NO: 2, and having amino acid residues 9 to 27 of SEQ ID NO: 2 are disclosed, which are together named C-terminal polypeptides of CKLF1. Also disclosed is a pharmaceutical composition containing a therapeutically effective amount of the CKLF1 C-terminal polypeptide and pharmaceutically acceptable salts, carrier or excipient. Further disclosed are the polynucleotides encoding the C-terminal polypeptides of CKLF1, and vectors and host cells containing the polynucleotides; the in vitro assays for detecting the expression level of the polypeptide or polynucleotide in a test sample; and the monoclonal or polyclonal antibodies against the polypeptides or active fragments thereof. The polypeptides of the present invention can be pharmaceutically used for treating the HIV infection, allergic disease, allograft rejection, diseases in brain and autoimmune diseases.

Abstract: The present invention provides chemokine-like factor (CKLF) polypeptides with chemotactic and hematopoietic stimulating activities and polynucleotides encoding such polypeptides. Additionally, a method for producing such CKLF polypeptides by recombinant techniques is provided. Also provided are the antibodies and antagonists against such polypeptides. The present invention further disclose a drug compound comprising a therapeutically effective amount of such CKLF polypeptides as well as pharmaceutically acceptable excipients and carriers. Also disclosed are the uses of such CKLF polypeptides and polynucleotides in diagnostics or therapeutics to treat immunodeficiency, hematopoietic diseases and primary tumors.

Abstract: The present invention provides chemokine-like factor (CKLF) polypeptides with chemotactic and hematopoietic stimulating activities and polynucleotides encoding such polypeptides. Additionally, a method for producing such CKLF polypeptides by recombinant techniques is provided. Also provided are the antibodies and antagonists against such polypeptides. The present invention further disclose a drug compound comprising a therapeutically effective amount of such CKLF polypeptides as well as pharmaceutically acceptable excipients and carriers. Also disclosed are the uses of such CKLF polypeptides and polynucleotides in diagnostics or therapeutics to treat immunodeficiency, hematopoietic diseases and primary tumors.

Abstract: The present invention provides chemokine-like factor (CKLF) polypeptides with chemotactic and hematopoietic stimulating activities and polynucleotides encoding such polypeptides. Additionally, a method for producing such CKLF polypeptides by recombinant techniques is provided. Also provided are the antibodies and antagonists against such polypeptides. The present invention further disclose a drug compound comprising a therapeutically effective amount of such CKLF polypeptides as well as pharmaceutically acceptable excipients and carriers. Also disclosed are the uses of such CKLF polypeptides and polynucleotides in diagnostics or therapeutics to treat immunodeficiency, hematopoietic diseases and primary tumors.